Pharmaceutics, Vol. 15, Pages 990: A Review on Dry Eye Disease Treatment: Recent Progress, Diagnostics, and Future Perspectives

Pharmaceutics, Vol. 15, Pages 990: A Review on Dry Eye Disease Treatment: Recent Progress, Diagnostics, and Future Perspectives

Pharmaceutics doi: 10.3390/pharmaceutics15030990

Authors: Himangsu Mondal Ho-Joong Kim Nijaya Mohanto Jun-Pil Jee

Dry eye disease is a multifactorial disorder of the eye and tear film with potential damage to the ocular surface. Various treatment approaches for this disorder aim to alleviate disease symptoms and restore the normal ophthalmic environment. The most widely used dosage form is eye drops of different drugs with 5% bioavailability. The use of contact lenses to deliver drugs increases bioavailability by up to 50%. Cyclosporin A is a hydrophobic drug loaded onto contact lenses to treat dry eye disease with significant improvement. The tear is a source of vital biomarkers for various systemic and ocular disorders. Several biomarkers related to dry eye disease have been identified. Contact lens sensing technology has become sufficiently advanced to detect specific biomarkers and predict disease conditions accurately. This review focuses on dry eye disease treatment with cyclosporin A-loaded contact lenses, contact lens biosensors for ocular biomarkers of dry eye disease, and the possibility of integrating sensors in therapeutic contact lenses.